Immunotherapy cocktail takes on tough throat cancer
NCT ID NCT07392320
First seen Feb 06, 2026 · Last updated Jun 23, 2026 · Updated 18 times
Summary
This study tests whether adding an immunotherapy drug (penpulimab) to standard chemotherapy and radiation, followed by maintenance immunotherapy, works better than the usual maintenance drug capecitabine for people with high-risk nasopharyngeal cancer. About 142 participants with advanced disease will be randomly assigned to one of two treatment groups. The goal is to see which approach better prevents the cancer from returning or spreading.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARANGEAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Penpulimab (immunotherapy drug) combined with chemotherapy (docetaxel, cisplatin) and radiation, compared to capecitabine (chemotherapy pill)
What this could lead to
If this works, it could offer a more effective treatment plan for high-risk nasopharyngeal cancer, potentially improving survival without the cancer coming back.
What could go wrong
This is a small, early-phase (Phase 2) trial, so results may not apply to everyone. Immunotherapy can cause immune-related side effects, and the added benefit over standard care is not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.